We opine that single small molecules armed with combo σ-1 stimulatory and HDAC-6 and antioxidant or OS inhibitory properties could offer a novel multi-mechanistic approach for developing anti-neurodegenerative and potentially disease-modifying agents for AD. Here, HDAC6 is linked to Alzheimer disease.